Amjevita is supplied as a 40mg/0.8mL single-dose prefilled SureClick autoinjector, and as 20mg/0.4mL and 40mg/0.8mL single-dose prefilled syringes.
Diagnosis & Disease Information
Follow-Up Colonoscopy Rates Low After Positive Stool-Based Test
Follow-up colonoscopy rates were 43.3% within 90 days, 56.1% within 360 days of positive stool-based screening test result
Risk for Advanced Neoplasm Low 10+ Years After Negative Colonoscopy
Prevalence of advanced neoplasms 40 to 50% lower among those who underwent repeated screening ≥10 years after a negative colonoscopy
Tukysa Combo Approved for RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
The approval was based on data from the phase 2 MOUNTAINEER trial, which included patients with HER2-positive unresectable or metastatic colorectal cancer.
Immunotherapy Combo Reduces Risk of Cancer Recurrence in Early-Stage Liver Cancer
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
PD-1 Inhibitor Treatment Effective for Localized Mismatch Repair-Deficient CRC
84.9 percent of 73 patients achieved objective response, including 23.3 percent with complete response
December 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
FDA to Review Etrasimod NDA for Ulcerative Colitis
Etrasimod is an oral selective sphingosine 1-phosphate (S1P) receptor modulator currently being investigated to treat a range of immuno-inflammatory diseases.
Idacio, a Citrate-Free Biosimilar to Humira, Gets FDA Approval
The approval for Idacio was based on a review of data that showed similar pharmacokinetics, efficacy, safety, and immunogenicity to the reference adalimumab product.
